Sodium
Active ingredient
Sold as Bridged Phenyl Combination… · GAVISCON ORIGINAL ANISEED… · MAGNESIUM TRISILICATE…
- Drug class
- -
- Availability
- Prescription and OTC
- Routes
- Intravenous, Oral, Topical
- Markets covered
- 3
- Products on record
- 55
- FDA reports (12 mo)
- 92,881
Overview
Plain-language summary, compiled from the cited regulatory records
Sodium is an active ingredient used in medications. It is indicated for the immediate reduction of blood pressure in hypertensive crises for adult and pediatric patients [1]. Concomitant longer-acting antihypertensive medication should be administered to minimize the duration of treatment with sodium nitroprusside [1]. Sodium nitroprusside is also indicated for producing controlled hypotension to reduce bleeding during surgery [1]. Additionally, it is indicated for the treatment of acute conditions [1].
Sodium nitroprusside is available under various brand names, including Bridged Phenyl Combination 9312 [1]. In the past 12 months, there have been 92,881 adverse event reports associated with this ingredient [2]. The most frequently reported issues include off-label use, the drug being ineffective, fatigue, nausea, and headache [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 44 | May 29, 2026 |
| CA Canada | Health Canada | 6 | July 24, 2025 |
| US United States | FDA | 5 | January 28, 2026 |
GBUnited Kingdom· MHRA
44 products
Uses
For the treatment of chronic constipation.
How to take
CACanada· Health Canada
6 products
Uses
20 Product Monograph: Sodium Nitroprusside for Injection Page 3 of 22 PrSodium Nitroprusside for Injection 25 mg/mL PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Administration Dosage Form / Strength Nonmedicinal Ingredients Intravenous Solution for injection; 25 mg/mL Water for Injection INDICATIONS AND CLINICAL USE Sodium Nitroprusside for Injection is indicated for the treatment of acute hypertension, refractory to standard therapeutic measures.
Sodium Nitroprusside for Injection is also indicated for producing controlled hypotension during anesthesia in order to reduce bleeding in surgical procedures, where surgeon and anesthesiologist deem it appropriate. In each case, the benefit-risk ratio should be carefully considered on an individual basis.
CONTRAINDICATIONS Patients who are hypersensitive to sodium nitroprusside or to any ingredient in the formulation or component of the container. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING. , arteriovenous shunt or coarctation of the aorta).
USUnited States· FDA
5 products
Uses
INDICATIONS AND USAGE
Sodium phenylbutyrate tablets are indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).
It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy.
It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium phenylbutyrate tablets must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation (see Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section).
Sources & citations
- [1]MHRA (UK) · PL556120072 · revised May 29, 2026
- [2]Health Canada (DPD) · 02450089 · revised March 22, 2025
- [3]FDA DailyMed · 0c76d25b-abac-41… · revised January 28, 2026 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.